TP-3654

DRUG2 trials

Sponsors

Sumitomo Pharma America, Inc.

Conditions

Advanced Solid TumorsMyelofibroses

Phase 1

Study of TP-3654 in Patients With Advanced Solid Tumors

CompletedNCT03715504

Sumitomo Pharma America, Inc.Advanced Solid Tumors

Start: 2019-04-16End: 2021-07-08Updated: 2023-11-14

TP-3654 Food Effect Study

CompletedNCT07492355

Sumitomo Pharma America, Inc.Myelofibroses

Start: 2024-03-04End: 2024-05-31Updated: 2026-03-25

Related Papers

Abstract P223: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors

Molecular Cancer Therapeutics2021-12-01

Abstract 1345: Pharmacodynamic biomarkers for Pim inhibition with TP-3654 in patients with solid tumors

Cancer Research2021-07-01